Evidence map›Paper›PMID 41912547›Full record

ArticleNature communications2026

Domain gain or loss in a fungal chitinase enables specialization towards antagonism or immune suppression.

Ruben Eichfeld, Asmamaw B Endeshaw, Margareta J Hellmann, Taim Nassr, Bruno M Moerschbacher, Alga Zuccaro

Abstract read
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ruben EichfeldUniversity of Cologne, Institute for Plant Sciences, Cologne, Germany.
Asmamaw B EndeshawUniversity of Cologne, Institute for Plant Sciences, Cologne, Germany.
Margareta J HellmannUniversity of Münster, Institute of Biology and Biotechnology of Plants, Münster, Germany.ORCID 0000-0002-3500-9465
Taim NassrUniversity of Cologne, Institute for Plant Sciences, Cologne, Germany.ORCID 0009-0007-8258-1644
Bruno M MoerschbacherUniversity of Münster, Institute of Biology and Biotechnology of Plants, Münster, Germany.ORCID 0000-0001-6067-3205
Alga ZuccaroUniversity of Cologne, Institute for Plant Sciences, Cologne, Germany. azuccaro@uni-koeln.de.ORCID 0000-0002-8026-0114

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Effector proteins orchestrate interactions that determine host compatibility and microbial competition. Among these are microbial chitinases, widespread enzymes involved in nutrient acquisition, fungal cell-wall remodelling, and antagonism, yet how their functions diversify across ecological roles remains unclear. Here, we show that modular domain variation within a conserved GH18 chitinase family enables specialization between microbial antagonism and host immune suppression in the beneficial root endophyte Serendipita indica. The chitinase SiCHIT, bearing a C-terminal CBM5 domain, is induced during fungal confrontation and inhibits growth of the phytopathogen Bipolaris sorokiniana, thereby protecting host roots. Deleting CBM5 abolishes this antagonistic activity, whereas grafting CBM5 onto its paralog SiCHIT2, which lacks this domain, confers antifungal function. In contrast, SiCHIT2 is induced during root colonization and suppresses chitin-triggered immunity, promoting host compatibility. These results show how domain loss and regulatory divergence can reprogram antimicrobial enzymes into immune-suppressive effectors in beneficial plant-associated fungi.

Indexed as

AscomycotaBipolarisChitinasesFungal ProteinsAmino Acid SequenceChitinPlant RootsProtein DomainsChitinChitinasesFungal Proteins

Identifiers

PMID41912547
PMCPMC13039781

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.